MINT MINT, Dpt of Biology, University of Rome Tor Vergata MINT http://mint.bio.uniroma2.it/mint url>http://mint.bio.uniroma2.it/mint/ https://mint.bio.uniroma2.it MINT-[0-9]+ https://mint.bio.uniroma2.it/index.php/results-interactions/?id=${ac} The Molecular INTeraction database (MINT) is a relational database designed to store interactions between biological molecules. http://mint.bio.uniroma2.it Polymerization of MIP-1 chemokine (CCL3 and CCL4) and clearance of MIP-1 by insulin-degrading enzyme. Polymerization of MIP-1 chemokine (CCL3 and CCL4) and clearance of MIP-1 by insulin-degrading enzyme. EMBO J. (0261-4189) 2010 imex curation Ren M., Guo Q., Guo L., Lenz M., Qian F., Koenen RR., Xu H., Schilling AB., Weber C., Ye RD., Dinner AR., Tang WJ. Only protein-protein interactions in vitro In vitro saxs x ray scattering saxs predetermined predetermined participant predetermined Ren M., Guo Q., Guo L., Lenz M., Qian F., Koenen RR., Xu H., Schilling AB., Weber C., Ye RD., Dinner AR., Tang WJ. EMBO J. (0261-4189) 2010 Only protein-protein interactions imex curation Polymerization of MIP-1 chemokine (CCL3 and CCL4) and clearance of MIP-1 by insulin-degrading enzyme. Polymerization of MIP-1 chemokine (CCL3 and CCL4) and clearance of MIP-1 by insulin-degrading enzyme. EMBO J. (0261-4189) 2010 imex curation Ren M., Guo Q., Guo L., Lenz M., Qian F., Koenen RR., Xu H., Schilling AB., Weber C., Ye RD., Dinner AR., Tang WJ. Only protein-protein interactions in vitro In vitro competition binding competition binding predetermined predetermined participant predetermined Ren M., Guo Q., Guo L., Lenz M., Qian F., Koenen RR., Xu H., Schilling AB., Weber C., Ye RD., Dinner AR., Tang WJ. EMBO J. (0261-4189) 2010 Only protein-protein interactions imex curation Polymerization of MIP-1 chemokine (CCL3 and CCL4) and clearance of MIP-1 by insulin-degrading enzyme. Polymerization of MIP-1 chemokine (CCL3 and CCL4) and clearance of MIP-1 by insulin-degrading enzyme. EMBO J. (0261-4189) 2010 imex curation Ren M., Guo Q., Guo L., Lenz M., Qian F., Koenen RR., Xu H., Schilling AB., Weber C., Ye RD., Dinner AR., Tang WJ. Only protein-protein interactions in vitro In vitro x-ray diffraction x-ray crystallography X-ray X-ray x-ray diffraction predetermined predetermined participant predetermined Ren M., Guo Q., Guo L., Lenz M., Qian F., Koenen RR., Xu H., Schilling AB., Weber C., Ye RD., Dinner AR., Tang WJ. EMBO J. (0261-4189) 2010 Only protein-protein interactions imex curation Polymerization of MIP-1 chemokine (CCL3 and CCL4) and clearance of MIP-1 by insulin-degrading enzyme. Polymerization of MIP-1 chemokine (CCL3 and CCL4) and clearance of MIP-1 by insulin-degrading enzyme. EMBO J. (0261-4189) 2010 imex curation Ren M., Guo Q., Guo L., Lenz M., Qian F., Koenen RR., Xu H., Schilling AB., Weber C., Ye RD., Dinner AR., Tang WJ. Only protein-protein interactions in vitro In vitro molecular sieving molecular sieving Gel Filtration Size Exclusion Chromatography Size Exclusion Chromatography Gel Filtration Sizing column predetermined predetermined participant predetermined Ren M., Guo Q., Guo L., Lenz M., Qian F., Koenen RR., Xu H., Schilling AB., Weber C., Ye RD., Dinner AR., Tang WJ. EMBO J. (0261-4189) 2010 Only protein-protein interactions imex curation Polymerization of MIP-1 chemokine (CCL3 and CCL4) and clearance of MIP-1 by insulin-degrading enzyme. Polymerization of MIP-1 chemokine (CCL3 and CCL4) and clearance of MIP-1 by insulin-degrading enzyme. EMBO J. (0261-4189) 2010 imex curation Ren M., Guo Q., Guo L., Lenz M., Qian F., Koenen RR., Xu H., Schilling AB., Weber C., Ye RD., Dinner AR., Tang WJ. Only protein-protein interactions in vitro In vitro protease assay protease assay predetermined predetermined participant predetermined Ren M., Guo Q., Guo L., Lenz M., Qian F., Koenen RR., Xu H., Schilling AB., Weber C., Ye RD., Dinner AR., Tang WJ. EMBO J. (0261-4189) 2010 Only protein-protein interactions imex curation ide_human Insulin-degrading enzyme IDE Insulin protease Insulysin Abeta-degrading protease protein protein human Homo sapiens Human MRYRLAWLLHPALPSTFRSVLGARLPPPERLCGFQKKTYSKMNNPAIKRIGNHITKSPEDKREYRGLELANGIKVLLISDPTTDKSSAALDVHIGSLSDPPNIAGLSHFCEHMLFLGTKKYPKENEYSQFLSEHAGSSNAFTSGEHTNYYFDVSHEHLEGALDRFAQFFLCPLFDESCKDREVNAVDSEHEKNVMNDAWRLFQLEKATGNPKHPFSKFGTGNKYTLETRPNQEGIDVRQELLKFHSAYYSSNLMAVCVLGRESLDDLTNLVVKLFSEVENKNVPLPEFPEHPFQEEHLKQLYKIVPIKDIRNLYVTFPIPDLQKYYKSNPGHYLGHLIGHEGPGSLLSELKSKGWVNTLVGGQKEGARGFMFFIINVDLTEEGLLHVEDIILHMFQYIQKLRAEGPQEWVFQECKDLNAVAFRFKDKERPRGYTSKIAGILHYYPLEEVLTAEYLLEEFRPDLIEMVLDKLRPENVRVAIVSKSFEGKTDRTEEWYGTQYKQEAIPDEVIKKWQNADLNGKFKLPTKNEFIPTNFEILPLEKEATPYPALIKDTAMSKLWFKQDDKFFLPKACLNFEFFSPFAYVDPLHCNMAYLYLELLKDSLNEYAYAAELAGLSYDLQNTIYGMYLSVKGYNDKQPILLKKIIEKMATFEIDEKRFEIIKEAYMRSLNNFRAEQPHQHAMYYLRLLMTEVAWTKDELKEALDDVTLPRLKAFIPQLLSRLHIEALLHGNITKQAALGIMQMVEDTLIEHAHTKPLLPSQLVRYREVQLPDRGWFVYQQRNEVHNNCGIEIYYQTDMQSTSENMFLELFCQIISEPCFNTLRTKEQLGYIVFSGPRRANGIQGLRFIIQSEKPPHYLESRVEAFLITMEKSIEDMTEEAFQKHIQALAIRRLDKPKKLSAECAKYWGEIISQQYNFDRDNTEVAYLKTLTKEDIIKFYKEMLAVDAPRRHKVSVHVLAREMDSCPVVGEFPCQNDINLSQAPALPQPEVIQNMTEFKRGLPLFPLVKPHINFMAAKL 8A28AEF75EDA0EDA ccl4_human C-C motif chemokine 4 CCL4 LAG1 MIP1B SCYA4 G-26 T-lymphocyte-secreted protein HC21 Lymphocyte activation gene 1 protein MIP-1-beta(1-69) Macrophage inflammatory protein 1-beta PAT 744 Protein H400 SIS-gamma Small-inducible cytokine A4 T-cell activation protein 2 protein protein human Homo sapiens Human MKLCVTVLSLLMLVAAFCSPALSAPMGSDPPTACCFSYTARKLPRNFVVDYYETSSLCSQPAVVFQTKRSKQVCADPSESWVQEYVYDLELN DIP protein P13236 original sequence version: 159 F2EA7CF341B0E258 ccl3_human C-C motif chemokine 3 CCL3 G0S19-1 MIP1A SCYA3 Small-inducible cytokine A3 SIS-beta PAT 464.1 Macrophage inflammatory protein 1-alpha Tonsillar lymphocyte LD78 alpha protein G0/G1 switch regulatory protein 19-1 protein protein human Homo sapiens Human MQVSTAALAVLLCTMALCNQFSASLAADTPTACCFSYTSRQIPQNFIADYFETSSQCSKPGVIFLTKRSRQVCADPSEEWVQKYVSDLELSA DIP protein P10147 original sequence version: 169 mint Monokine with inflammatory and chemokinetic properties. Binds to CCR1, CCR4 and CCR5. One of the major HIV-suppressive factors produced by CD8+ T-cells. Recombinant MIP-1-alpha induces a dose-dependent inhibition of different strains of HIV-1, HIV-2, and simian immunodeficiency virus (SIV) 517865D5D6776CA8 ccl3 3 MIP-1A 8 predetermined predetermined participant predetermined predetermined predetermined participant predetermined unspecified role unspecified role neutral component neutral component purified purified Stoichiometry: 2.0 direct interaction direct interaction mint The MIP-1 polymer structures reveal for the first time the novel interaction between the MIP-1 dimers that lead to polymerization. t1 f1a f1b f1c f1d f1e f1f f1g f2 sf4 st1 ccl4 3 MIP-1B 7 predetermined predetermined participant predetermined predetermined predetermined participant predetermined unspecified role unspecified role neutral component neutral component purified purified Stoichiometry: 2.0 direct interaction direct interaction mint The MIP-1 polymer structures reveal for the first time the novel interaction between the MIP-1 dimers that lead to polymerization. t1 f1c f1d f1e f1f f1g sf4 ccl3-ide 3 MIP-1A 8 predetermined predetermined participant predetermined predetermined predetermined participant predetermined unspecified role unspecified role neutral component neutral component purified purified IDE 6 predetermined predetermined participant predetermined predetermined predetermined participant predetermined unspecified role unspecified role neutral component neutral component purified purified direct interaction direct interaction homomint mint f7a f7b f7c f7d t1 sf2 ccl3-1 4 MIP-1A 8 predetermined predetermined participant predetermined predetermined predetermined participant predetermined unspecified role unspecified role neutral component neutral component purified purified undefined mutation mutation decreasing interaction mutation decreasing mutation decreasing interaction hotspot hotspot mutation decreasing mutation analysis mutation analysis certain certain sequence position certain certain certain sequence position certain Wed Jul 06 17:02:55 BST 2016 Sequence change details about this feature cannot be ascertained or do not fit with the current version of the referenced protein, so they have been deleted as a result of our quality control procedures. The original label was 'mutation decreasing' Asp27Ala Stoichiometry: 2.0 direct interaction direct interaction mint SEC data confirmed that both MIP-1a and MIP-1b behaved as high-MW polymers as previously reported (Figure 3A). The MW of MIP-1a and MIP-1b at 1mg/ml are approximately 400 600 and 600 3000 kDa, respectively. f3a sf7 ccl4-1 4 MIP-1B 7 predetermined predetermined participant predetermined predetermined predetermined participant predetermined unspecified role unspecified role neutral component neutral component purified purified Stoichiometry: 2.0 direct interaction direct interaction mint SEC data confirmed that both MIP-1a and MIP-1b behaved as high-MW polymers as previously reported (Figure 3A). The MW of MIP-1a and MIP-1b at 1mg/ml are approximately 400 600 and 600 3000 kDa, respectively. f3a sf7 ccl4-1 1 MIP-1B 7 predetermined predetermined participant predetermined predetermined predetermined participant predetermined unspecified role unspecified role neutral component neutral component purified purified Stoichiometry: 2.0 direct interaction direct interaction mint The SAXS data agree with the MIP-1 polymer structures. f3b sf6 st2 ccl3-1 1 MIP-1A 8 predetermined predetermined participant predetermined predetermined predetermined participant predetermined unspecified role unspecified role neutral component neutral component purified purified undefined mutation mutation decreasing interaction mutation decreasing mutation decreasing interaction hotspot hotspot mutation decreasing mutation analysis mutation analysis certain certain sequence position certain certain certain sequence position certain Wed Jul 06 17:07:56 BST 2016 Sequence change details about this feature cannot be ascertained or do not fit with the current version of the referenced protein, so they have been deleted as a result of our quality control procedures. The original label was 'mutation decreasing' Asp27Ala Stoichiometry: 2.0 direct interaction direct interaction mint The SAXS data agree with the MIP-1 polymer structures. SAXS data indicated that the MIP-1 alpha D27A mutant yields shorter polymers than the wild-type MIP-1 alpha (Figure 3B, Supplementary Table 2). f3b sf6 st2 ccl3-ide-1 5 MIP-1A 8 ms participant Identification by mass spectrometry ms participant predetermined predetermined participant predetermined enzyme target enzyme target substrate substrate neutral component neutral component purified purified IDE 6 predetermined predetermined participant predetermined predetermined predetermined participant predetermined enzyme enzyme neutral component neutral component purified purified cleavage cleavage reaction cleavage homomint mint MALDI-TOF mass spectrometry (MS) analyses indicate that IDE indeed can cleave both MIP-1a and MIP-1b. f5b sf10 ccl4-ide 5 IDE 6 predetermined predetermined participant predetermined predetermined predetermined participant predetermined enzyme enzyme neutral component neutral component purified purified MIP-1B 7 ms participant Identification by mass spectrometry ms participant predetermined predetermined participant predetermined enzyme target enzyme target substrate substrate neutral component neutral component purified purified cleavage cleavage reaction cleavage homomint mint MALDI-TOF mass spectrometry (MS) analyses indicate that IDE indeed can cleave both MIP-1a and MIP-1b. f5b sf10 ccl3-ide-2 2 MIP-1A 8 predetermined predetermined participant predetermined predetermined predetermined participant predetermined unspecified role unspecified role neutral component neutral component purified purified IDE 6 predetermined predetermined participant predetermined predetermined predetermined participant predetermined enzyme target enzyme target substrate substrate neutral component neutral component purified purified direct interaction direct interaction f6a homomint mint We first assessed the ability of MIP-1a to compete with the degradation of the fluorogenic bradykinin-mimetic peptide, Substrate V by recombinant human IDE (Figure 6A). The IC50 value of MIP-1a is B170 nM